Landmark Bio and Galapagos have signed a multi-year strategic manufacturing agreement for the manufacture of the latter’s oncology chimeric antigen receptor (CAR) T-cell therapy clinical programmes at the point of care.

The details of the agreement’s financial terms were not revealed.

Landmark Bio will manufacture clinical trial batches of Galapagos’ CAR-T cell therapies for haematology-oncology in compliance with Good Manufacturing Practice standards in the Boston metropolitan area, US.

The manufacturing agreement seeks to implement Galapagos’ decentralised CAR-T manufacturing model, which allows clinicians to administer CAR T-cells within a median of seven days of leukapheresis, overcoming key limitations of existing CAR-T treatments.

Landmark Bio CEO Ran Zheng stated: “We are excited to partner with Galapagos to support their CAR-T clinical development programmes in the US.

“This strategic manufacturing collaboration is a testament to our expertise in cell and gene therapy manufacturing and underscores our commitment to bring more life-saving therapies to patients faster.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Landmark Bio operates a 44,000ft² fully integrated development and manufacturing facility, which offers laboratory space for translational research early development, process and analytical development, and technology innovation.

The biomanufacturing area includes nine cleanrooms for cell therapies, genome editing, viral vector, mRNA, lipid nanoparticle production, fill and finish and in-house quality control testing.

The company also offers wraparound services such as drug development, regulatory consulting and programme management.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.